Form 8-K - Current report:
SEC Accession No. 0001650664-24-000114
Filing Date
2024-10-22
Accepted
2024-10-22 07:04:58
Documents
15
Period of Report
2024-10-22
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K edit-20241022.htm   iXBRL 8-K 28858
2 EX-99 editasmedicinestrategicupd.htm EX-99 33479
6 image_0a.jpg GRAPHIC 10702
  Complete submission text file 0001650664-24-000114.txt   208994

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT edit-20241022.xsd EX-101.SCH 1875
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT edit-20241022_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT edit-20241022_pre.xml EX-101.PRE 12591
17 EXTRACTED XBRL INSTANCE DOCUMENT edit-20241022_htm.xml XML 2714
Mailing Address 11 HURLEY ST. CAMBRIDGE MA 02141
Business Address 11 HURLEY ST. CAMBRIDGE MA 02141 617-401-9000
Editas Medicine, Inc. (Filer) CIK: 0001650664 (see all company filings)

EIN.: 464097528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37687 | Film No.: 241384658
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)